Follow Slashdot stories on Twitter

 



Forgot your password?
typodupeerror
×

Comment Re:"Creationists" (Score 1) 220

The AC does have a point: "creationism" (and "intelligent design") are potentially ambiguous terms to people who aren't engaged in the evolution debate.

Then if they want to engage in that debate, they should learn how those terms are used. AC's sub-Objectivist ranting doesn't make me think he's interested in that level of intellectual effort, though.

Comment Re:in related news (Score 1) 77

Participation in fraud and selling stolen goods is hardly capitalism. ... Maybe you should look into the theory of capitalism a bit and this time read past the title and forward of the books.

Maybe you should look at how things work in the real world instead of believing what a bunch of philosophers tell you they think ought to happen. Hint: Karl Marx and Ayn Rand both developed economic theories that were entirely logical and self-consistent.

Comment Re:Creativity vs. Being a Crank (Score 2) 118

Yes. This is an important distinction. "They also laughed at Bozo the Clown."

Hoyle wasn't purely a crank, of course. He was a very good scientist, who had made major contributions to his field, but who just couldn't accept new ideas past a certain point, and thereby became a crank. This phenomenon isn't universal by any means, but it's sadly common.

Comment Re:Poster should consider going back to the clinic (Score 3, Informative) 64

The actual benefits from pharmacogenetic testing for Warfarin metabolism are swamped by all the other factors which affect Warfarin metabolism (eg diet and other meds).

The FDA disagrees, and so does the evidence. And there are a whole lot of areas where pharmacogenetics is starting to have an impact on treatment. In any case, pharmacogenetics is a subset of pharmacogenomics; for example, as I mentioned in another comment, the lab where I work is working on expression-based tests for prediction of altitude sickness and setting up drug trials.

Comment Re:Regulatory hurdles (Score 4, Insightful) 64

The clinical trials framework that's evolved over the decades isn't really equipped to deal with personalized medicine, but that's starting to change. Where I work, we're starting to understand the genomic basis of altitude sickness and putting together treatment trials on that basis. This is an area where the potential market is pretty large, of course, and for rare diseases that affect small numbers of people it's going to be harder, but if we can develop a generally accepted body of protocols for individualized trials then it should be possible to apply this to smaller groups as time goes by.

Slashdot Top Deals

For God's sake, stop researching for a while and begin to think!

Working...